Merck & Co. (MRK) lifts full-year 2026 sales outlook, raises EPS midpoint
Merck & Co. has raised its full-year 2026 sales guidance to a range of $65.8 billion to $67.0 billion, simultaneously lifting its non-GAAP earnings per share midpoint to $5.10. The updated outlook follows the pharmaceutical company's first-quarter 2026 results, which reported sales of $16.3 billion.
Q1 Performance and Outlook Revision
The company's oncology blockbuster, KEYTRUDA, contributed $8.03 billion to the first-quarter sales. While GAAP earnings per share were impacted by charges associated with recent acquisitions, the revised guidance signals management's confidence in future performance. Merck completed its acquisition of Terns Pharmaceuticals on April 30, 2026. This development continues the narrative from earlier this month when Merck's shares rose after the company delivered strong Q1 earnings and pipeline developments on May 12.
Merck & Co. shares are trading at $112.20, up 0.7% from Friday's close of $111.38. The stock had seen a 1.8% decline on Friday, May 15, following a flat performance earlier in the week.
What Merck's Upgraded Outlook Signals for its Future
Merck & Co. operates as a global pharmaceutical company, dedicated to discovering, developing, manufacturing, and selling a wide range of medicines, vaccines, and animal health products. Their business centres on addressing various diseases and conditions, with key revenue drivers often being innovative treatments for cancer, infectious diseases, and other complex health challenges. Their customers are primarily healthcare providers, governments, and patients worldwide, who rely on their products for treatment and prevention.
Today's positive movement stems directly from Merck's decision to raise its full-year 2026 sales guidance to a range of $65.8 billion to $67.0 billion, alongside lifting its non-GAAP earnings per share midpoint to $5.10. This updated outlook, following robust first-quarter 2026 sales of $16.3 billion which included $8.03 billion from its oncology blockbuster KEYTRUDA, signals management's increased confidence in the company's future performance, despite recent acquisition-related charges and a previous stock dip on 15 May. The company's acquisition of Terns Pharmaceuticals on 30 April 2026, and strong Q1 earnings reported on 12 May, underpin this revised forecast.
This upward revision in expected performance has resonated with investors, as Merck & Co. shares are currently trading at $112.20, marking a 0.7% rise from Friday's close of $111.38.
Think of it like a seasoned chef who, after a successful breakfast service, announces they're expecting to serve significantly more diners for dinner than originally planned, and with a higher profit margin per dish. This isn't just a hopeful guess; it implies they've secured better ingredients, streamlined their kitchen, or seen an unexpected surge in bookings. For a company like Merck, raising its financial guidance suggests it sees clearer paths to higher sales and earnings than it did before.
Merck & Co.
Merck & Co., Inc. (MRK) operates as a global healthcare enterprise, specialising in pharmaceutical and animal health solutions. Its Pharmaceutical division develops human health products spanning oncology, immunology, neuroscience, and cardiovascular conditions, alongside a portfolio of vaccines for paediatric, adolescent, and adult populations. The Animal Health segment focuses on veterinary pharmaceuticals, vaccines, and health management services, including digital identification and monitoring tools. Merck serves a diverse client base, from drug wholesalers and hospitals to managed healthcare providers, physicians, veterinarians, and animal producers. The firm also engages in strategic collaborations, including partnerships with AstraZeneca PLC and Gilead Sciences, Inc. for HIV treatments. Established in 1891, Merck & Co., Inc. is headquartered in Kenilworth, New Jersey.